Last edition
News about "Budesonide capsules"
Zydus Gets USFDA Tentative Nod for Budesonide Delayed-Release Capsules, 4 mg
Zydus has received tentative approval from the US Food and Drug Administration (USFDA) for its Budesonide delayed-release capsules, 4 mg. The drug is indicated for the treatment of mild to moderate active Crohn’s disease affecting the ileum and/or ascending colon in adults and children aged eight years and above.
Budesonide Capsules | 05/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members